15 news items
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
TAK
18 Jun 24
values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
TAK
17 Jun 24
commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
TAK
14 Jun 24
people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have
HEALWELL AI's Pentavere Announces Partnership with Takeda to Support Rare Disease Real-World Evidence Analysis for Patients living with Hereditary Angioedema
TAK
6 Jun 24
by their commitment to patients, their people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics
Takeda's TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
TAK
3 Jun 24
headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries
397ytavg9fe60ntm6e7zz6drhxen1q16fmfjrsldt0wjun
PFE
TAK
1 Jun 24
headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions
bcglvuc2ncins6tjv6wykig6p
TAK
31 May 24
-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our
v8wiu016sxj9xyip6luii ke77zwffnuxm5vkvyaws
TAK
16 May 24
people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience
qr9mnyl0d56547i2 h82e1kxszp5c2cd9aiz9nxh6twwariwh
ACIU
TAK
13 May 24
in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our
s1a77jbi86sh4sewmzz6mz81eondyye41dxmme0xyr 44d
ACIU
TAK
13 May 24
and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us
o1qht03kudlfgdp32tyqikl
TAK
9 May 24
values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our
mzxiic s5psshpofz7wvg87e3l08wx6entdp0f3rhg1lcasyv2z6gpv187
TAK
26 Apr 24
and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us
d2veqnhh3h4 9ssg7cmabr
TAK
22 Apr 24
to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded
muqegnekv 8v
TAK
18 Apr 24
headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries
dkm89oc2enc2kxgpylrzw1i79fxdetgy42w3z lgvr9bj37
TAK
26 Mar 24
values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet
- Prev
- 1
- Next